Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by Noloon Nov 16, 2019 5:08pm
253 Views
Post# 30360839

RE:RE:Conference Call

RE:RE:Conference Call
davewho wrote: I listened to the CC again last night. A couple things I missed.

James said they are expecting their 1st Analyst coverage. It will be interesting to read that report and see who is doing it..

He also said break even for SZLS is 3-4k tests / month. Exas does 130k / month and is still loosing money. If TeleHeath and Oncore can bring the test count anywhere close to Exas's numbers StageZero will have so much free cash flow they won't know how to spend it all.



Thanks Dave. There's a lot of stuff covered in this CC, way more than in any other CCs from this year. Nicely done too, since Tripp decided to structure it as a FAQ. I'm not saying it answers everything. On the contrary. But it was the best one by far in 2019. 

I'll listen to it again tomorrow. I'm sure some people here didn't even bother to give it a try, which is a shame. 
Bullboard Posts